Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan M Murphy

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Cell Science|June 18, 2020
Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factorTigist Y Tamir, Brittany M Bowman, Megan J Agajanian, et al.
Oncogene|May 16, 2022
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in miceSamera H Hamad, Stephanie A Montgomery, Jeremy M Simon, et al.
Oncogene|August 24, 2022
Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in miceSamera H Hamad, Stephanie A Montgomery, Jeremy M Simon, et al.
The Journal of Pathology|July 4, 2020
A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissueBrittany M Bowman, Stephanie A Montgomery, Travis P Schrank, et al.
Cancer Research Communications|September 23, 2022
Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck CancerRyan M Murphy, Jason Tasoulas, Alessandro Porrello, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Cell Science|June 18, 2020
Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factorTigist Y Tamir, Brittany M Bowman, Megan J Agajanian, et al.
Oncogene|May 16, 2022
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in miceSamera H Hamad, Stephanie A Montgomery, Jeremy M Simon, et al.
Oncogene|August 24, 2022
Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in miceSamera H Hamad, Stephanie A Montgomery, Jeremy M Simon, et al.
The Journal of Pathology|July 4, 2020
A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissueBrittany M Bowman, Stephanie A Montgomery, Travis P Schrank, et al.
Cancer Research Communications|September 23, 2022
Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck CancerRyan M Murphy, Jason Tasoulas, Alessandro Porrello, et al.
Pageof 2